S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
Log in
NASDAQ:LJPC

La Jolla Pharmaceutical Stock Forecast, Price & News

$4.92
-0.14 (-2.77 %)
(As of 03/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.77
Now: $4.92
$5.16
50-Day Range
$5.04
MA: $6.10
$7.51
52-Week Range
$3.36
Now: $4.92
$8.10
Volume559,431 shs
Average Volume1.38 million shs
Market Capitalization$134.71 million
P/E RatioN/A
Dividend YieldN/A
Beta2.84
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), an investigational product to treat conditions characterized by iron overload. The company was founded in 1989 and is headquartered in San Diego, California.
La Jolla Pharmaceutical logo

Headlines

LJPC Nov 2020 3.000 call
October 30, 2020 |  uk.finance.yahoo.com
La Jolla Pharmaceutical announces CMO departure
September 18, 2020 |  seekingalpha.com
La Jolla Pharma +3.2% as director buys $187,000 worth
August 24, 2020 |  seekingalpha.com
La Jolla to acquire Tetraphase Pharma
June 24, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LJPC
CUSIPN/A
Phone858-207-4264
Employees90
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.05 million
Book Value($2.21) per share

Profitability

Net Income$-116,510,000.00
Net Margins-205.85%

Miscellaneous

Market Cap$134.71 million
Next Earnings DateN/A
OptionableOptionable

MarketRank

Overall MarketRank

1.68 out of 5 stars

Medical Sector

254th out of 1,968 stocks

Biological Products, Except Diagnostic Industry

28th out of 177 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$4.92
-0.14 (-2.77 %)
(As of 03/3/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LJPC News and Ratings via Email

Sign-up to receive the latest news and ratings for LJPC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











La Jolla Pharmaceutical (NASDAQ:LJPC) Frequently Asked Questions

Is La Jolla Pharmaceutical a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for La Jolla Pharmaceutical in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" La Jolla Pharmaceutical stock.
View analyst ratings for La Jolla Pharmaceutical
or view top-rated stocks.

What stocks does MarketBeat like better than La Jolla Pharmaceutical?

Wall Street analysts have given La Jolla Pharmaceutical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but La Jolla Pharmaceutical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were La Jolla Pharmaceutical's earnings last quarter?

La Jolla Pharmaceutical (NASDAQ:LJPC) issued its quarterly earnings data on Saturday, November, 14th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.54) by $0.11. The biopharmaceutical company earned $9.07 million during the quarter.
View La Jolla Pharmaceutical's earnings history
.

How has La Jolla Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

La Jolla Pharmaceutical's stock was trading at $4.81 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LJPC shares have increased by 2.3% and is now trading at $4.92.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for LJPC?

1 brokers have issued 12-month price objectives for La Jolla Pharmaceutical's stock. Their forecasts range from $8.00 to $8.00. On average, they anticipate La Jolla Pharmaceutical's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 62.6% from the stock's current price.
View analysts' price targets for La Jolla Pharmaceutical
or view top-rated stocks among Wall Street analysts.

Who are La Jolla Pharmaceutical's key executives?

La Jolla Pharmaceutical's management team includes the following people:
  • Dr. Lakhmir S. Chawla, Consultant (Age 50, Pay $560.21k)
  • Mr. Larry G. Edwards, Pres, CEO & Director (Age 49)
  • Mr. Michael S. Hearne, CFO, Principal Financial & Accounting Officer (Age 58)
  • Ms. Paula Rusu, VP of Operations
  • Ms. Sandra Vedrick, Sr. Director of Investor Relations & HR
  • Mr. Thomas Ouellette, VP of Sales & Marketing
  • Mr. Luke Seikkula, Sr. VP of Pharmaceutical Operations (Age 57)
  • Mr. Stewart M. Kroll, Chief Devel. Officer (Age 62)
  • Mr. Mark D. Williams, Sr. VP of Medical Affairs

What is George F. Tidmarsh's approval rating as La Jolla Pharmaceutical's CEO?

8 employees have rated La Jolla Pharmaceutical CEO George F. Tidmarsh on Glassdoor.com. George F. Tidmarsh has an approval rating of 49% among La Jolla Pharmaceutical's employees. This puts George F. Tidmarsh in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of La Jolla Pharmaceutical's key competitors?

What other stocks do shareholders of La Jolla Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other La Jolla Pharmaceutical investors own include BioCryst Pharmaceuticals (BCRX), Intercept Pharmaceuticals (ICPT), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Advanced Micro Devices (AMD), El Pollo Loco (LOCO), Sarepta Therapeutics (SRPT), Inovio Pharmaceuticals (INO), NVIDIA (NVDA) and XOMA (XOMA).

What is La Jolla Pharmaceutical's stock symbol?

La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC."

Who are La Jolla Pharmaceutical's major shareholders?

La Jolla Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.40%), Alyeska Investment Group L.P. (1.96%), Alyeska Investment Group L.P. (1.96%), Northern Trust Corp (0.91%), Nuveen Asset Management LLC (0.58%) and First Midwest Bank Trust Division (0.57%). Company insiders that own La Jolla Pharmaceutical stock include Darryl Wellinghoff, David A Ramsay and Kevin C Tang.
View institutional ownership trends for La Jolla Pharmaceutical
.

Which institutional investors are selling La Jolla Pharmaceutical stock?

LJPC stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, Wells Fargo & Company MN, RMR Wealth Builders, Signaturefd LLC, JPMorgan Chase & Co., and Bank of New York Mellon Corp.
View insider buying and selling activity for La Jolla Pharmaceutical
or view top insider-selling stocks.

Which institutional investors are buying La Jolla Pharmaceutical stock?

LJPC stock was bought by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, Renaissance Technologies LLC, Alyeska Investment Group L.P., Alyeska Investment Group L.P., BlackRock Inc., Virtu Financial LLC, Nuveen Asset Management LLC, and Walleye Capital LLC. Company insiders that have bought La Jolla Pharmaceutical stock in the last two years include Darryl Wellinghoff, David A Ramsay, and Kevin C Tang.
View insider buying and selling activity for La Jolla Pharmaceutical
or or view top insider-buying stocks.

How do I buy shares of La Jolla Pharmaceutical?

Shares of LJPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is La Jolla Pharmaceutical's stock price today?

One share of LJPC stock can currently be purchased for approximately $4.92.

How much money does La Jolla Pharmaceutical make?

La Jolla Pharmaceutical has a market capitalization of $134.71 million and generates $23.05 million in revenue each year. The biopharmaceutical company earns $-116,510,000.00 in net income (profit) each year or ($4.30) on an earnings per share basis.

How many employees does La Jolla Pharmaceutical have?

La Jolla Pharmaceutical employs 90 workers across the globe.

What is La Jolla Pharmaceutical's official website?

The official website for La Jolla Pharmaceutical is www.lajollapharmaceutical.com.

Where are La Jolla Pharmaceutical's headquarters?

La Jolla Pharmaceutical is headquartered at 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121.

How can I contact La Jolla Pharmaceutical?

La Jolla Pharmaceutical's mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-207-4264 or via email at [email protected]


This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.